Serpin Pharma, Inc.
Serpin Pharma is a biotechnology company developing peptide therapeutics for inflammatory diseases. Its lead candidate is designed to activate a receptor involved in regulating inflammation and cellular survival. The company reports preclinical research and clinical development programs across cardiovascular, kidney, neurological, and skin indications.
Industries
N/A
Serpin Pharma, Inc.
Products
An investigational peptide therapeutic derived from a natural serine protease inhibitor protein and modified to target LRP1. It is being studied for inflammatory conditions, with reported clinical and preclinical work across cardiac, kidney, neurological, and skin indications.
An injectable development program listed for acute kidney injury, acute myocardial infarction, and chemotherapy-induced peripheral neuropathy.
A topical and injectable development program listed for severe skin diseases.
An oral development program listed for rheumatoid arthritis, multiple sclerosis, and lupus.
A program listed for skin-care applications and described as licensed for cosmetics.
An investigational peptide therapeutic derived from a natural serine protease inhibitor protein and modified to target LRP1. It is being studied for inflammatory conditions, with reported clinical and preclinical work across cardiac, kidney, neurological, and skin indications.
An injectable development program listed for acute kidney injury, acute myocardial infarction, and chemotherapy-induced peripheral neuropathy.
A topical and injectable development program listed for severe skin diseases.
An oral development program listed for rheumatoid arthritis, multiple sclerosis, and lupus.
A program listed for skin-care applications and described as licensed for cosmetics.
Expertise Areas
- Inflammatory disease therapeutics
- Immunomodulation
- Peptide drug development
- Cardiovascular inflammation
Key Technologies
- SERPIN-derived peptides
- LRP1 receptor agonism
- Peptide sequence modification
- ERK and AKT signaling
News & Updates
A published clinical study of the safety and tolerability of a peptide that mimics a receptor-binding portion of alpha-1 antitrypsin.
A research article examining the peptide’s effects on inflammatory molecules and viral replication in central nervous system cells.
The company reported FDA clearance of an investigational new drug application to support a Phase 1b trial for chemotherapy-induced peripheral neuropathy.
The company reported approval to begin enrolling participants in a Phase II study evaluating its candidate in patients with chronic kidney disease undergoing cardiac bypass surgery.
The company reported receiving a $2 million National Cancer Institute Phase II Small Business Innovation Research grant to support clinical development of a peptide candidate for chemotherapy-induced peripheral neuropathy.
The company reported receiving a $900,000 grant to advance a randomized controlled Phase 2a trial evaluating an anti-inflammatory candidate in acute myocardial infarction.
A published clinical study of the safety and tolerability of a peptide that mimics a receptor-binding portion of alpha-1 antitrypsin.
A research article examining the peptide’s effects on inflammatory molecules and viral replication in central nervous system cells.
The company reported FDA clearance of an investigational new drug application to support a Phase 1b trial for chemotherapy-induced peripheral neuropathy.
The company reported approval to begin enrolling participants in a Phase II study evaluating its candidate in patients with chronic kidney disease undergoing cardiac bypass surgery.
The company reported receiving a $2 million National Cancer Institute Phase II Small Business Innovation Research grant to support clinical development of a peptide candidate for chemotherapy-induced peripheral neuropathy.
The company reported receiving a $900,000 grant to advance a randomized controlled Phase 2a trial evaluating an anti-inflammatory candidate in acute myocardial infarction.